Ipidacrine (Tablets, Solution) Instructions for Use
ATC Code
N06DA05 (Ipidacrine)
Active Substance
Ipidacrine (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Cholinesterase inhibitor
Pharmacotherapeutic Group
Psychoanaleptics; agents for the treatment of dementia; anticholinesterase agents
Pharmacological Action
Cholinesterase inhibitor. Prevents the enzymatic hydrolysis of acetylcholine and prolongs its action. Blocks potassium channels of membranes and promotes their depolarization. Stimulates synaptic transmission in neuromuscular junctions, conduction of excitation in nerve fibers, enhances the effect on smooth muscles of acetylcholine and other mediators (including epinephrine, serotonin, histamine, oxytocin), restores neuromuscular transmission and conduction of excitation in the peripheral nervous system (due to disorders of various origins: trauma, inflammation, action of local anesthetics, antibiotics, toxins, potassium chloride).
Increases the tone and contractility of the smooth muscles of internal organs, including the gastrointestinal tract and bronchi (up to bronchospasm), decreases heart rate, enhances the secretion of salivary glands, the contractile activity of the myometrium, and the tone of skeletal muscles.
It has a stimulating effect on the central nervous system in combination with individual manifestations of a sedative effect; promotes improvement of learning and memory.
Indications
Diseases of the peripheral nervous system (neuritis, polyneuritis, polyneuropathy, polyradiculopathy), bulbar paralysis and paresis.
In the recovery period for organic lesions of the central nervous system, accompanied by motor and/or cognitive impairments.
Myasthenia gravis, myasthenic syndrome.
Demyelinating diseases (as part of complex therapy).
Alzheimer’s disease, senile dementia of the Alzheimer’s type.
Functional disorders of the central nervous system (memory impairment, decreased ability to concentrate, motivation, initiative, disorientation, emotional lability, etc.) in encephalopathy (of traumatic, vascular and other origins), cerebrovascular accident, traumatic brain injury, cerebral dysfunction with learning difficulties in children.
Weakness of labor.
Intestinal atony.
Intoxication with anticholinergic agents.
ICD codes
| ICD-10 code | Indication |
| F00 | Dementia in Alzheimer’s disease |
| F07 | Personality and behavioral disorders due to disease, damage or dysfunction of the brain |
| F81 | Specific developmental disorders of scholastic skills |
| G12.2 | Motor neuron disease |
| G30 | Alzheimer’s disease |
| G35 | Multiple sclerosis |
| G36 | Other form of acute disseminated demyelination |
| G37 | Other demyelinating diseases of the central nervous system |
| G54 | Lesions of nerve roots and plexuses |
| G60 | Hereditary and idiopathic neuropathy |
| G61 | Inflammatory polyneuropathy |
| G62.1 | Alcoholic polyneuropathy |
| G63.2 | Diabetic polyneuropathy |
| G70 | Myasthenia gravis and other disorders of the neuromuscular junction |
| G93.4 | Unspecified encephalopathy |
| I69 | Sequelae of cerebrovascular diseases |
| K59.8 | Other specified functional intestinal disorders |
| M54.1 | Radiculopathy |
| M79.2 | Neuralgia and neuritis, unspecified |
| O62 | Abnormalities of forces of labor |
| T44.3 | Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, not elsewhere classified |
| T90 | Sequelae of injuries of head |
| ICD-11 code | Indication |
| 6A03.Z | Developmental learning disorder, unspecified |
| 6D80.Z | Dementia due to Alzheimer’s disease, onset unknown or unspecified |
| 6D8Z | Dementia, unknown or unspecified cause |
| 6E68 | Secondary emotionally labile personality disorder |
| 6E6Z | Unspecified secondary mental or behavioral syndromes |
| 8A20 | Alzheimer’s disease |
| 8A40.Z | Multiple sclerosis, unspecified |
| 8A41.Z | Isolated demyelinating syndromes of the central nervous system, unspecified |
| 8A42.Z | Acute disseminated encephalomyelitis, unspecified |
| 8A4Z | Multiple sclerosis or other white matter disorders, unspecified |
| 8B25.Z | Sequelae of cerebrovascular disease, unspecified |
| 8B60.Z | Motor neuron disease, unspecified |
| 8B6Y | Other specified motor neuron diseases or related disorders |
| 8B6Z | Motor neuron diseases or related disorders, unspecified |
| 8B93.Z | Radiculopathy, unspecified |
| 8B9Z | Diseases of nerve roots or plexuses, unspecified |
| 8C01.Z | Inflammatory polyneuropathy, unspecified |
| 8C03.0 | Diabetic polyneuropathy |
| 8C2Y | Other specified hereditary neuropathy |
| 8C4Z | Disorders of nerve roots, plexuses or peripheral nerves, unspecified |
| 8C6Z | Myasthenia gravis or other specified diseases of the neuromuscular junction, unspecified |
| 8D44.0 | Alcoholic polyneuropathy |
| 8E47 | Encephalopathy, not elsewhere classified |
| 8E4A.0 | Paraneoplastic or autoimmune disorders of the central nervous system, including brain and spinal cord |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| 8E63 | Post-cardiopulmonary bypass encephalopathy |
| DB32.3 | Acquired hypoganglionosis of the colon |
| DB32.Z | Colonic motility disorders, unspecified |
| DD90.2 | Functional heartburn |
| DD91.Y | Other specified irritable bowel syndrome or functional bowel disorders |
| DD93.Y | Other specified functional gastrointestinal disorders in infants, toddlers and school-age children |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| JB02.Z | Abnormalities of forces of labor, unspecified |
| NA0Z | Head injury, unspecified |
| NE60 | Poisoning by drugs, medicaments or biological substances, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally, subcutaneously, or intramuscularly.
For subcutaneous or intramuscular injection, use a single dose of 5 mg to 30 mg.
The maximum daily dose is 200 mg; do not exceed this limit.
For peripheral nervous system diseases (neuritis, polyneuropathy), use 10 mg to 40 mg orally three to four times daily.
For central nervous system disorders (Alzheimer’s disease, dementia, post-traumatic conditions), initiate therapy with 10 mg orally two to three times daily.
Gradually increase the dose based on tolerance and clinical response.
For myasthenia gravis and myasthenic syndromes, titrate the dose individually, monitoring for cholinergic effects.
For intestinal atony, administer 10 mg to 20 mg subcutaneously or intramuscularly.
For weakness of labor, use a 5 mg to 10 mg subcutaneous or intramuscular injection.
Adjust the frequency and duration of therapy according to the specific indication and patient response.
In elderly patients or those with hepatic/renal impairment, initiate treatment at the lower end of the dosing range.
Monitor for signs of cholinergic excess, particularly when increasing the dose.
Adverse Reactions
From the digestive system anorexia, hypersalivation, nausea, vomiting, increased peristalsis, diarrhea, jaundice.
From the central nervous system dizziness (after repeated application), ataxia.
Allergic reactions skin rash, itching.
Other manifestations of m-cholinomimetic action – bronchospasm, bradycardia.
Contraindications
Epilepsy, extrapyramidal disorders with hyperkinesis, angina pectoris, severe bradycardia, bronchial asthma, vestibular disorders, gastric and duodenal ulcer in the acute phase; mechanical obstruction of the intestine or urinary tract; pregnancy, lactation period, children and adolescents under 18 years of age; hypersensitivity to ipidacrine.
Use in Pregnancy and Lactation
Use during pregnancy and breastfeeding is contraindicated.
Pediatric Use
Use in children and adolescents under 18 years of age is contraindicated.
Special Precautions
Use with caution in gastric ulcer, thyrotoxicosis, cardiovascular diseases. The ability of ipidacrine to increase uterine tone should be taken into account.
During treatment, alcohol consumption should be avoided, as ethanol enhances the side effects of ipidacrine.
Effect on ability to drive vehicles and operate machinery
Should not be used in patients whose activities involve driving vehicles and work requiring high concentration and speed of psychomotor reactions.
Drug Interactions
With simultaneous use, Ipidacrine enhances the sedative effect of drugs that have a depressant effect on the central nervous system, ethanol, the effect of other cholinesterase inhibitors and m-cholinomimetics.
In patients with myasthenia gravis, when using ipidacrine against the background of other cholinergic agents, the risk of developing a cholinergic crisis increases.
With simultaneous use with beta-blockers, bradycardia increases.
Ipidacrine weakens the effect of local anesthetics, antibiotics, potassium chloride.
Atropine and methoctinium iodide reduce the severity of overdose symptoms.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Tablets 20 mg
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Form
 |
Ipidacrine | Tablets 20 mg |
Dosage Form, Packaging, and Composition
Tablets
| 1 tab. | |
| Ipidacrine | 20 mg |
10 pcs. – blister packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – blister packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – blister packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – blister packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – blister packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
20 pcs. – blister packs – cardboard packs (20 pcs.) – By prescription
20 pcs. – blister packs (2 pcs.) – cardboard packs (40 pcs.) – By prescription
20 pcs. – blister packs (3 pcs.) – cardboard packs (60 pcs.) – By prescription
20 pcs. – blister packs (4 pcs.) – cardboard packs (80 pcs.) – By prescription
20 pcs. – blister packs (5 pcs.) – cardboard packs (100 pcs.) – By prescription
50 pcs. – blister packs – cardboard packs (50 pcs.) – By prescription
50 pcs. – blister packs (2 pcs.) – cardboard packs (100 pcs.) – By prescription
50 pcs. – blister packs (3 pcs.) – cardboard packs (150 pcs.) – By prescription
50 pcs. – blister packs (4 pcs.) – cardboard packs (200 pcs.) – By prescription
50 pcs. – blister packs (5 pcs.) – cardboard packs (250 pcs.) – By prescription
Solution for intramuscular and subcutaneous administration 5 mg/1 ml: amp. 5, 10, 15 or 20 pcs.
Solution for intramuscular and subcutaneous administration 15 mg/1 ml: amp. 5, 10, 15 or 20 pcs.
Marketing Authorization Holder
Promomed Rus LLC (Russia)
Manufactured By
Biokhimik, JSC (Russia)
Dosage Forms
|
Ipidacrine | Solution for intramuscular and subcutaneous administration 5 mg/1 ml: amp. 5, 10, 15 or 20 pcs. |
| Solution for intramuscular and subcutaneous administration 15 mg/1 ml: amp. 5, 10, 15 or 20 pcs. |
Dosage Form, Packaging, and Composition
Solution for intramuscular and subcutaneous administration transparent, colorless.
| 1 ml | |
| Ipidacrine hydrochloride monohydrate | 5.4 mg |
| Equivalent to ipidacrine hydrochloride content | 5 mg |
Excipients : 1M hydrochloric acid solution, water for injections.
1 ml – ampoules (5) – blister packs (1) – cardboard packs.
1 ml – ampoules (5) – blister packs (2) – cardboard packs.
1 ml – ampoules (5) – blister packs (3) – cardboard packs.
1 ml – ampoules (5) – blister packs (4) – cardboard packs.
Solution for intramuscular and subcutaneous administration transparent, colorless.
| 1 ml | |
| Ipidacrine hydrochloride monohydrate | 16.2 mg |
| Equivalent to ipidacrine hydrochloride content | 15 mg |
Excipients : 1M hydrochloric acid solution, water for injections.
1 ml – ampoules (5) – blister packs (1) – cardboard packs.
1 ml – ampoules (5) – blister packs (2) – cardboard packs.
1 ml – ampoules (5) – blister packs (3) – cardboard packs.
1 ml – ampoules (5) – blister packs (4) – cardboard packs.
Solution for intramuscular and subcutaneous administration 5 mg/ml
Solution for intramuscular and subcutaneous administration 15 mg/ml
Marketing Authorization Holder
Rif LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Forms
|
Ipidacrine | Solution for intramuscular and subcutaneous administration 5 mg/ml |
| Solution for intramuscular and subcutaneous administration 15 mg/ml |
Dosage Form, Packaging, and Composition
Solution for intramuscular and subcutaneous administration
| 1 ml | |
| Ipidacrine | 5 mg |
1 ml – ampoules (10 pcs.) – cardboard packs – By prescription
1 ml – ampoules (5 pcs.) – cardboard packs – By prescription
Solution for intramuscular and subcutaneous administration
| 1 ml | |
| Ipidacrine | 15 mg |
1 ml – ampoules (10 pcs.) – cardboard packs – By prescription
1 ml – ampoules (5 pcs.) – cardboard packs – By prescription
Tablets 20 mg
Marketing Authorization Holder
Pharmproekt, JSC (Russia)
Dosage Form
|
Ipidacrine | Tablets 20 mg |
Dosage Form, Packaging, and Composition
Tablets
| 1 tab. | |
| Ipidacrine | 20 mg |
10 pcs. – blister packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – blister packs (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – blister packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – blister packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – blister packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – blister packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – blister packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – blister packs (7 pcs.) – cardboard packs (70 pcs.) – By prescription
10 pcs. – blister packs (8 pcs.) – cardboard packs (80 pcs.) – By prescription
10 pcs. – blister packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
120 pcs. – jars – cardboard packs (120 pcs.) – By prescription
120 pcs. – bottles – cardboard packs (120 pcs.) – By prescription
14 pcs. – blister packs – cardboard packs (14 pcs.) – By prescription
14 pcs. – blister packs (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – blister packs (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – blister packs (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – blister packs (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – blister packs (5 pcs.) – cardboard packs (70 pcs.) – By prescription
14 pcs. – blister packs (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – blister packs (7 pcs.) – cardboard packs (98 pcs.) – By prescription
14 pcs. – blister packs (8 pcs.) – cardboard packs (112 pcs.) – By prescription
14 pcs. – blister packs (9 pcs.) – cardboard packs (126 pcs.) – By prescription
30 pcs. – jars – cardboard packs (30 pcs.) – By prescription
30 pcs. – bottles – cardboard packs (30 pcs.) – By prescription
60 pcs. – jars – cardboard packs (60 pcs.) – By prescription
60 pcs. – bottles – cardboard packs (60 pcs.) – By prescription
7 pcs. – blister packs – cardboard packs (7 pcs.) – By prescription
7 pcs. – blister packs (10 pcs.) – cardboard packs (70 pcs.) – By prescription
7 pcs. – blister packs (2 pcs.) – cardboard packs (14 pcs.) – By prescription
7 pcs. – blister packs (3 pcs.) – cardboard packs (21 pcs.) – By prescription
7 pcs. – blister packs (4 pcs.) – cardboard packs (28 pcs.) – By prescription
7 pcs. – blister packs (5 pcs.) – cardboard packs (35 pcs.) – By prescription
7 pcs. – blister packs (6 pcs.) – cardboard packs (42 pcs.) – By prescription
7 pcs. – blister packs (7 pcs.) – cardboard packs (49 pcs.) – By prescription
7 pcs. – blister packs (8 pcs.) – cardboard packs (56 pcs.) – By prescription
7 pcs. – blister packs (9 pcs.) – cardboard packs (63 pcs.) – By prescription
90 pcs. – jars – cardboard packs (90 pcs.) – By prescription
90 pcs. – bottles – cardboard packs (90 pcs.) – By prescription
Solution for intramuscular and subcutaneous administration 5 mg/ml
Solution for intramuscular and subcutaneous administration 15 mg/ml
Marketing Authorization Holder
Severnaya Zvezda NAO (Russia)
Dosage Forms
|
Ipidacrine-SZ | Solution for intramuscular and subcutaneous administration 5 mg/ml |
| Solution for intramuscular and subcutaneous administration 15 mg/ml |
Dosage Form, Packaging, and Composition
Solution for intramuscular and subcutaneous administration
| 1 ml | |
| Ipidacrine hydrochloride | 5 mg |
1 ml – ampoules (10 pcs.) – carton packs – By prescription
Solution for intramuscular and subcutaneous administration
| 1 ml | |
| Ipidacrine hydrochloride | 15 mg |
1 ml – ampoules (10 pcs.) – carton packs – By prescription
![Ipidacrine [Tablets, Solution] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Ipidacrine [Tablets, Solution] 2")